An audit of tumour marker requests in Northern Ireland

Annals of Clinical Biochemistry

Volumn 41, Issue 5, 2004, Pages 378-384

  McDonnell, Margaret ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; TUMOR MARKER;

ARTICLE; BREAST TUMOR; CANCER DIAGNOSIS; CLINICAL LABORATORY; CLINICAL PRACTICE; COLORECTAL TUMOR; HUMAN; IRELAND; LABORATORY TEST; LIVER TUMOR; MAJOR CLINICAL STUDY; MEDICAL AUDIT; OVARY TUMOR; PANCREAS TUMOR; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; STOMACH TUMOR; TESTIS TUMOR; TUMOR DIAGNOSIS;

HUMANS; MEDICAL AUDIT; NORTHERN IRELAND; QUESTIONNAIRES; TUMOR MARKERS, BIOLOGICAL;

EID: 4644249315     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563041731655     Document Type: Article

References (15)

1. Association of Clinical Biochemists in Ireland. Guidelines for the use of tumour markers, 1999. http://www.iol.ie/-deskenny/acbi.html (accessed May 2002)
2. Lamerz R, Albrecht W, Bialk P, Dati F, Duffy MJ, Gerl E, et al. Tumour markers in germ cell cancers: EGTM recommendations. Anticancer Res 1999; 19: 2795-8
3. Klapdor R, Aronsson AC, Duffy MJ, Hansson LO, Khalifa R, Lamerz R, et al. Tumour markers in gastrointestinal cancers: EGTM recommendations. Anticancer Res 1999; 19: 2811-5
4. Bonfrer JMG, Duffy MJ, Radtke M, Segurado O, Torre GC, van Dalen A, et al. Tumour markers in gynaecological cancers: EGTM recommendations. Anticancer Res 1999; 19: 2807-10
5. Bast RC, Bates S, Bredt AB, Desch CE, Pritsche H, Fues L, et al. Clinical practice guidelines for the use of tumour markers in breast and colorectal cancer. J Clin Oncol 1996; 14: 2843-77
6. The Regional Audit Group in Chemical Pathology. Tumour marker audit report. Northern Ireland Medical Review 2000; 16: 8-9
7. Guidelines for the provision of interpretative comments on biochemical reports. Bull Roy Coll Pathol 1998; 104: 25
8. Sturgeon C, Dati F, Duffy U, Hasholzner R, Klapador R, Lamerz I, et al. Quality requirements and control: EGTM recommendations. Anticancer Res 1999; 19: 2791-4
9. McGinley J, Kilpatrick ES. Tumour markers: their use and misuse by clinicians. Ann Clin Biochem 2003; 40: 639-42
10. Duffy MJ. CA19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998; 35: 364-70
11. Sturgeon C. Practice guidelines for tumour marker use in the clinic. Clin Chem 2002; 48: 1151-9
12. Rustin GJ. The clinical value of tumour markers in the management of ovarian cancer. Ann Clin Biochem 1996; 33: 284-9
13. Wanebo HJ, Rao B, Pinsky CM, Hoffman RG, Stearns M, Schwartz MK, et al. N Engl J Med 1978; 299: 448-51
14. Solomon DH, Hashimoto H, Daltry L, Liang MH. Techniques to improve Physicians' use of diagnostic tests. JAMA 1998; 280: 2020-7
15. Foy R, MacLennan G, Grimshaw J, Penney G, Campbell M, Grol R. Attributes of clinical recommendations that influence change in practice following audit and feedback. J Clin Epidemiol 2002; 55: 717-22